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The first structure of a receptor tyrosine kinase domain:
a further step in understanding the molecular basis
of insulin action
Both the observed cis-inhibition and the proposed trans-activation of the insulin
receptor tyrosine kinase help explain insulin signalling through its receptor.
Structure 15 January 1995, 3:1-6
The dramatic clinical onset of diabetes, usually in chil-
dren and adolescents, together with its subsequent fatal
course, have ensured insulin a prominent place in med-
ical history. Although insulin can be an effective therapy,
diabetes is still widespread throughout the world. Could
its treatment be advanced by understanding the insulin
receptor, which is a member of the tyrosine kinase fam-
ily, a group of enzymes that play a critical role in cell
division, metabolism and development [1]? An impor-
tant step towards an answer has been taken by the defini-
tion of the three-dimensional structure of the tyrosine
kinase domain of the insulin receptor reported recently
by Hubbard et al. [2].
The availability of insulin in a pure crystalline form for
the treatment of insulin-dependent diabetes in the 1920s
led to a focus on its characterization. This culminated in
the early determination of the sequence of insulin, its
complete chemical synthesis, and the determination of its
three-dimensional structure by X-ray analysis. The three-
dimensional structure showed that regions widely sepa-
rated in the primary structure, for example Al, A2, B25,
are brought together in the tertiary structure to provide a
region that might recognise the receptor [3]. In fact, the
large surface of the insulin molecule implicated in recep-
tor binding, suggest that insulin is almost surrounded by
its receptor. This is consistent with the finding that no
insulin mimetic small molecule can compete as a full
agonist at the receptor and no insulin modified at a single
amino acid residue is a full antagonist.
The insulin receptor
Cloning and sequencing the cDNA of the insulin recep-
tor [4,5] revealed similar features to those of other recep-
tor tyrosine kinases. These include an extracellular,
cystine-rich domain, followed by a single transmem-
brane, probably helical region, and an intracellular tyro-
sine kinase (Fig. 1). Unlike most receptor tyrosine
kinases, however, the insulin receptor, and also the
insulin-like growth factor I (IGF1) receptor, and insulin-
related receptor, are proteolytically processed into ao and
3 subunits that remain covalently associated by disul-
phide bond(s). These ot3 units are further disulphide-
linked to give the mature ()2 heterotetrameric
receptor.
Biochemical and affinity labelling demonstrated that the
extracellular domain of the receptor must be involved in
insulin binding. The sequences of the extracellular
domains for the insulin, IGF1 and epidermal growth fac-
tor (EGF) receptors include two large, homologous
domains (L) which in the human and Drosophila EGF
receptors are each followed by a series of smaller cystine-
rich domains (S), to give a gene-duplicated structure of
L1 S1 L2 S2 [6]. In the human insulin receptor, however,
the S domain is not repeated, but there are two
fibronectin type III domains in the extracellular sequence
[7], the first of which contains a large insert that spans
the ax- junction (Fig. 2).
Some progress has been made in identifying receptor
residues that are involved in binding insulin. Affinity
labelling of the receptor with various insulin derivatives
and crosslinking with bifunctional agents, followed by
isolation of the labelled fragments, has implicated residues
20-120 (I 1), the disulphide rich region (S), part of L
and the region immediately carboxy-terminal to it.
These determinants are largely present in the proteolysis-
resistant region that binds insulin [1]. This picture of
Fig. 1. The domain organisation of the insulin receptor.
Assignments of domain boundaries are based on [6] and [7]. The
receptor comprises the oa (red, orange + yellow) and (magenta,
purple + green) subunits, which are disulphide-bonded together.
There is a further disulphide bond, represented by the vertical
yellow bar, which joins the two a subunits of the tetramer. L1, L2
are the duplicated large domains each comprising four or five
copies of a helix-turn-strand motif; S is the cystine-rich domain,
which contains three repeats. The first fibronectin domain (F1) is
interrupted by an insert, believed to be independently folded,
which spans the a/,8 junction. T is the transmembrane helix; K is
the kinase domain. The lengths of the blocks correspond approx-
imately to the number of amino acid residues.
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Fig. 2. A 'pastiche model' of the insulin
receptor. This was assembled using
components from known structures (rib-
bon diagrams drawn with SETOR;
[381).The kinase domain was taken from
the insulin receptor kinase structure [2],
the fibronectin domains were taken
from the crystal structure of the tenth
type III cell adhesion module of human
fibronectin (pdblfna.pdb) and the
insulin from pdb4ins.pdb. The area car-
boxy-terminal to the kinase domain has
not been included. Red, orange and yel-
low (shaded) areas represent domains of
unknown secondary structure, drawn to
suggest their relative size; domain labels
as in Fig. 1, except Fnl and Fn2 repre-
sent the fibronectin domains.
insulin binding is supported by data from insulin-IGF
chimaeric receptors.
Studies with purified insulin receptor indicate that there
are two classes of binding site. At low concentrations of
hormone, a single monomer of insulin is bound. At
higher insulin concentrations, at least one further insulin
monomer binds, but with lower affinity. This, together
with the accelerated dissociation rate of labelled insulin
from the receptor in the presence of unlabelled insulin, is
characteristic of the phenomenon of 'negative coopera-
tivity'. Negative cooperativity has been interpreted either
in terms of competition for binding sites on the receptor
or in terms of insulin dimer formation competing with
insulin-receptor complexes. Most recently it has been
explained in terms of a model in which bound insulin
crosslinks the subunits of the receptor [8].
In many other cell surface receptor systems, ligand-
induced clustering of receptor components is the key to
activation of intracellular signalling cascades [9]. Because
of the pre-formed tetramer, the insulin receptor is likely
to use an alternative mechanism to activate its tyrosine
kinase; one possibility is that a conformational change
within the ot-subunit on binding insulin is followed by a
change of relative orientations of the two tyrosine kinases
in the dimer (Fig. 3).
After insulin binds to its receptor, the intrinsic tyrosine
kinase activity of the receptor is rapidly stimulated through
autophosphorylation. Three closely spaced tyrosine
residues within an 'activation loop' of the kinase domain
are believed to be responsible for this activation [10]. An
important consequence of activation is the recruitment of
insulin receptor substrate-i (IRS-1) and other effector
molecules such as phosphatidylinositol 3'-kinase (PI-3K),
Ras GTP activating protein (Ras GAP) and phospholipase
C-y (PLCyj and adaptor molecules, including Shc and
Grb2 [1]. Each of these effectors and adaptors contain Src
homology 2 (SH2) domains that bind phosphotyrosines
with high affinity. Importantly, it is IRS-1 that is the main
target for these SH2-containing proteins rather than the
insulin receptor itself [11], although recent evidence indi-
cates parallel pathways that are independent of IRS-1, for
activating PI-3K [12]. Eventually these transient com-
plexes formed with IRS-1 activate a number of pathways
involving serine/threonine kinases, such as the mitogen-
activated-protein (MAP) kinase which ultimately lead
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It is clear that control of tyrosine kinase activity is particu-
larly crucial to cellular function, given the key role it plays
in receiving and relaying extracellular information
through downstream cell signalling pathways [16]. Un-
controlled growth (oncogenesis) is a frequent consequence
of losing tight regulation. This can occur in a number of
ways, including gene fusion, over-expression of tyrosine
kinase, or point mutation within regions of negative
regulation such as the carboxyl terminus of Src [17].
Fig. 3. Binding and activation. Left and right, two possible
insulin-bound receptor conformers that could account for trans-
activation of the kinase; insulin monomer shown in blue. The lig-
and-free, inactive form of receptor is shown in the centre. The
left-hand model illustrates insulin binding to a surface that
includes the L1 and L2 domains of the same a-chain; on the
right, insulin binds to L1 and L2 domains from the two a-chains
of the complex. Two types of insulin-induced conformational
changes affecting the kinase domain can be envisaged. On the
left, a conformational change leads to a 'scissors' motion of the
two kinase domains to bring them into close enough juxtaposi-
tion for trans-activation; on the right, there is a relative rotation of
the two halves of the receptor to achieve this. In reality a combi-
nation of both pure motions is likely. Negative cooperativity
exhibited upon binding insulin is accounted for either In the
model, either through an unspecified conformational change
within the second a-chain to make binding of the second insulin
molecule more difficult (left-hand model); or rotation of the
respective half receptors (right-hand model) so that the second L1
and L2 sites are too far apart to form a site equivalent to the
occupied binding site. Small blue and white circles on the kinase
domain represent the three regulatory Tyr of the kinase domain
in their unphosphorylated or phosphorylated state respectively.
to the initiation of protein synthesis [13] and to the
translocation of an insulin-sensitive glucose transporter to
the cell surface [1].
The protein kinase family
Receptor tyrosine kinases such as the insulin receptor
belong to a much larger, diverse family of protein kinases
[14]. Members of the family catalyse the transfer of the
,y-phosphate moiety of ATP to covalently modify a spe-
cific side chain located on a protein substrate. In com-
mon with other intrinsic tyrosine kinases of growth
factor receptors, that of the insulin receptor can phos-
phorylate specific tyrosine side chains that have a particu-
lar local sequence environment, which generally include
a glutamate or aspartate immediately preceeding the
phosphorylated position and a hydrophobic residue
immediately following it [11]. Quite different determi-
nants are evident for the serine/threonine kinases class
[15]. In contrast to this difference in the specificity of
phosphorylation, many other features are shared
throughout the protein kinase family [14].
Most of what is known about kinase structure comes
from studies on serine/threonine protein kinases, (for
review, see [18]). Their overall molecular topology has a
bi-lobal organization, with a smaller, amino-terminal
lobe (N-lobe) containing the major determinants for
ATP binding, whereas the protein substrate binds at a
shallow cleft between the two lobes. The N-lobe con-
tains a twisted -sheet of five anti-parallel strands and is
linked to the larger, predominantly o-helical lobe (the
C-lobe), by a single stretch of residues. The roles of
many highly conserved residues within the protein kinase
family have been deduced from the ternary complex of
cAMP-dependant protein kinase (cAPK) bound to Mg-
ATP and a protein kinase inhibitor [19]. Most notably, an
aspartic acid side chain serves as a catalytic base for the
phosphotransfer, with a basic residue, typically lysine,
providing charge neutralization. An asparagine residue is
also conserved; it forms a hydrogen bond to the catalytic
aspartate and also coordinates the Mg2+ ion. In the
absence, until now, of any structural information on the
tyrosine kinases, models of their structures have drawn
heavily on structures of the serine/threonine class [20].
What is new about the insulin receptor tyrosine kinase
structure?
The newly determined structure of the insulin receptor
tyrosine kinase (IRK), in its apo, unphosphorylated form,
provides the first glimpse of a tyrosine kinase catalytic
domain [2]. The functional integrity of isolated domains,
such as the 306 amino acid fragment prepared by
Hubbard et al [2] has been known for some time from
various chimaeric growth factor receptors that are fully
functional [21].
It is not surprising that the overall tertiary fold of the
insulin receptor tyrosine kinase is similar to that of the
serine/threonine kinases, in view of the conservation of
many structural and functional features of protein kinases.
However, it is quite strikingly different in the detail and
positioning of several key secondary structure elements,
which are specific to tyrosine kinases. Thus the N-lobe of
insulin receptor tyrosine kinase lacks helix B of cAPK, as
do CDK2 and MAP kinase [20]. And, compared with
cAPK two additional short 3-strands (strands 310 and
[311) are found within the 'activation loop' of the insulin
receptor tyrosine kinase, but -strands 6 and 9 are
absent. The 'kinase insert' is located at a junction
between helix D and E. Receptor tyrosine kinases, such
as the platelet-derived growth factor (PDGF) receptor,
can have up to 90 residues inserted at this position.
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Fig. 4. (a) Molecular surface of the insulin receptor tyrosine kinase. The location of the two lobes and the approximate position of the
kinase insert are labelled. Also shown are the three regulatory tyrosines within the activation loop (green); three functional residues
within the catalytic loop (purple); and the P+1 loop including Trpl 175 and Prol 172 residues (yellow). (b) Close-up of the catalytic site
of IRK. Several key catalytic residues and tyrosine-kinase-specific residues are shown. Hydrogen bonds between Tyrl 162, Aspl 132 and
Arg 1136 are drawn as yellow dotted lines. Fig. 4 was drawn using GRASP [39] and provided by SR Hubbard, Columbia University.
Curiously, within this region the insulin receptor tyrosine
kinase has a proline-rich sequence which adopts a con-
formation similar to that of a consensus SH3 binding site
[22] (Fig. 4a). Although this insulin receptor-specific
motif has not been shown to bind SH3 domains, its
prominent location on the tyrosine kinase surface suggests
a functional role.
Perhaps the largest global difference between insulin
receptor tyrosine kinase and other kinase structures is the
extent to which the N- and C-lobes are rotated apart.
This open conformation of the insulin receptor kinase
involves a rotation of 26 ° compared with the closed form
of cAPK, and is similar to that seen for twitchin kinase
[23]. The lobes are held apart by steric interactions
involving a few highly conserved residues (Gly1005,
Phell51 and Gly1152, numbered according to [4]).
Clearly both lobes must be positioned closer together in
the activated form of the insulin receptor tyrosine kinase
to allow Lys1030, a key ATP-binding residue located in
the N-lobe, to lie in close proximity to the catalytic base
Asp1132. Such a motion most likely involves a rigid-
body movement of each lobe.
How is the tyrosine specificity encoded? The suggestion
that Tyr1162 mimics an incoming peptide substrate leads
to a convincing explanation of tyrosine substrate selectiv-
ity [2]. As Fig. 4b shows, the hydroxyl group of Tyrl 162
makes contacts with the catalytic Asp1132 and with
Argl 136. The positioning of the phenolic ring is guided
by the conformation of the P+1 loop (nomenclature
taken from cAPK, [24]), in particular by Prol172 and
to a lesser extent by Trp1175, two highly conserved
tyrosine-kinase-specific residues.
Although Tyr1162 is seemingly poised to be phosphory-
lated as if it were a substrate, the ATP-binding site is
blocked in the apo form of insulin receptor tyrosine
kinase by residues near the beginning of the activation
loop, namely Phell51 to Metll1153. It would seem there-
fore that Tyr1162 is inhibiting the insulin receptor tyro-
sine kinase in a cis fashion. Thus Hubbard et al. [2]
suggest that phosphorylation is unlikely to occur whilst
Tyrl162 is docked into the catalytic site, but that the
activation loop, including Tyrl 162, must move out of the
catalytic site to allow ATP to bind. Stabilization of a
non-inhibitory conformation of the activation loop may
occur upon phosphorylation of Tyr1158, Tyr1162 and
Tyr1163, a direct consequence of insulin binding to the
receptor ot subunit (Fig. 3). An important feature of this
model is that the receptor tyrosine kinase would have to
phosphorylate the three tyrosine sidechains on an adja-
cent receptor molecule, thus activating itself in a trans
manner. This proposed trans-activation is consistent with
biochemical data [25] and occurs in dominant negative
mutations of the insulin receptor [26]. Moreover, it is
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likely to be applicable to other closely related receptor
tyrosine kinases.
Despite the wealth of information provided by the
insulin receptor tyrosine kinase structure, several ques-
tions are unresolved. It is still not clear why this tyrosine
kinase has three regulatory tyrosine residues within its
activation loop. Mutation of any of these three tyrosines
to phenylalanine affects receptor autophosphorylation
and insulin signalling, though the degree of activation
depends on which tyrosine is substituted [1,27]. This
may suggest a specific role for each tyrosine, perhaps in
stabilizing or destabilizing either the Tyr 1162-engaged
or the Tyrl 162-disengaged conformer, depending on its
phosphorylation state. Is there a preferred order of phos-
phorylation of these three tyrosines? Does the Tyrl 162-
disengaged form have a defined conformation for the
activation loop once all three tyrosine sites have been
phosphorylated? Answers to these questions may
become apparent from structures of binary and ternary
complexes of activated insulin receptor tyrosine kinase
bound to peptide and Mg-ATP. It is likely that further
tyrosine kinase structures will illuminate other tyrosine
kinase-specific mechanisms of self-regulation, such as
that proposed for Src [28,29].
The future challenges in understanding insulin action
through its receptors
Although the definition of the three-dimensional struc-
tures of both insulin itself and the insulin receptor kinase
are important milestones, there is much to be done. The
structure of the complex of insulin with the receptor's
extracellular domain must be a first priority. Here the
challenge will be to obtain a receptor domain free of gly-
cosylation but maintaining high-affinity binding of
insulin. So far detailed structural information has been
obtained for only two ligand-receptor complexes, those
of growth hormone [30] and tumrnour necrosis factor [31].
Co-crystallization of an intact tyrosine kinase, or peptides
derived therefrom, complexed with SH2 domains of
adaptor molecules or portions of the IRS-1 molecule,
will also be a major goal. The structures of such com-
plexes will provide snapshots of regions of the insulin
receptor -subunit outside the boundaries of the kinase
domain prepared by Hubbard et al. [2]. In particular, the
amino-terminal juxtamembrane portion and the carboxy-
terminal 'tail' region both of which are phosphorylated at
multiple tyrosine sites (three Tyr in the juxtamembrane
region and two Tyr, close to the carboxyl terminus) sub-
sequent to insulin receptor activation. Though a clear role
for the carboxy-terminal tail in insulin signalling has not
been established, mutation of a single phosphotyrosyl
residue within the juxtamembrane portion dramatically
alters insulin-stimulated responses, apparently by impair-
ing the phosphorylation of key targets such as IRS-1 [32].
The long term goal must be to provide an integrated
view of insulin structure/function data. We must under-
stand in more detail than the simple models presented
here (Fig. 3) and elsewhere, how the binding of insulin
relates to processes occurring inside the cell, namely acti-
vation of the intrinsic tyrosine kinase domain and the
recruitment of important adaptor and effector molecules.
This example of the combination of key methodologies
in both molecular biology and protein crystallography
bodes well for the future of structural biology of signal
transduction. The identification and expression of func-
tional domains [33,34], the use of cryo-cooling and the
exploitation of X-ray synchrotron radiation to apply a
multiple anomalous dispersion (MAD) approach [35], will
all become important weapons in the crystallographer's
arsenal.
Does this new structural information provide any new
clinical prospects? Clearly, the structure of the insulin
receptor will provide a basis for rational exploration of
inhibitors that specifically inhibit this and other tyrosine
kinases [36]. Mutations throughout the insulin receptor
gene give rise to a variety of clinical syndromes, includ-
ing non insulin-dependent diabetes [11]. The insulin
receptor tyrosine kinase structure provides an insight as to
why a number of these mutations within the kinase
domain have such detrimental effects. There is also the
prospect of inactivating tyrosine kinases that are responsi-
ble for promoting oncogenesis, perhaps by introducing
dominant negative mutants into patients using a gene
therapy approach [37].
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